About Exelixis
Exelixis is a company based in San Francisco (United States) founded in 1994. The company has 1,150 employees as of December 31, 2024. Exelixis has completed 3 acquisitions, including Agritope, X-Ceptor Therapeutics and Xceptor. Exelixis offers products and services including CABOMETYX and COMETRIQ. Exelixis operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Employees 1150 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exelixis, Inc.
-
Annual Revenue
$2.17 B (USD)18.49as on Dec 31, 2024
-
Net Profit
$521.27 M (USD)150.89as on Dec 31, 2024
-
EBITDA
$718.75 M (USD)265.59as on Dec 31, 2024
-
Latest Funding Round
$366.84 K (USD), Grant
Jan 01, 2021
-
Investors
HHS
& 2 more
-
Employee Count
1150
as on Dec 31, 2024
-
Investments & Acquisitions
Agritope
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Exelixis
Exelixis is a publicly listed company on the NASDAQ with ticker symbol EXEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Exelixis
Exelixis offers a comprehensive portfolio of products and services, including CABOMETYX and COMETRIQ.
Treatment for advanced neuroendocrine tumors and other cancers.
Cabozantinib-based therapy for specific cancer types.
People of Exelixis
Unlock access to complete
Leadership Team
113 people
Finance and Accounting
23 people
Sales and Marketing
23 people
Software Development Team
23 people
Senior Team
21 people
Legal and Compliance
21 people
Product Management Team
11 people
Human Resources and Administration
10 people
Unlock access to complete
Funding Insights of Exelixis
Investors in Exelixis
Exelixis has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and OSTI.GOV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Scientific and technical information is managed and disseminated by OSTI.GOV.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Exelixis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exelixis
Exelixis has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Agritope, X-Ceptor Therapeutics and Xceptor.
Investment portfolio details for Exelixis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Data automation software is provided for financial markets operations.
|
Locked | Locked | 2003 | Locked | |
|
Nuclear receptor modulating small molecule drugs for metabolism and cardiovascular diseases
|
Locked | Locked | 1999 | Locked | |
|
Developer of transgenic varieties of fruit and vegetable crops
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Exelixis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Exelixis
Detailed financials for Exelixis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exelixis Comparisons
Peer comparison for Exelixis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exelixis
Exelixis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Exelixis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exelixis
Complete news archive for Exelixis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exelixis
Exelixis was founded in 1994 and raised its 1st funding round 11 years after it was founded.
Exelixis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
As of Dec 31, 2024, the latest employee count at Exelixis is 1,150.
Annual revenue of Exelixis is $2.17B as on Dec 31, 2024.
Exelixis was founded in 1994 in San Francisco, United States, within the biotechnology sector. Small molecule therapeutics for oncology are developed, with a focus on inhibiting key enzymes and proteins. Cabozantinib, the lead product, targets receptor tyrosine kinases for metastatic medullary thyroid cancer treatment. Cobimetinib addresses melanoma, while XL888 functions as an oral HSP90 inhibitor affecting regulatory proteins. Operations center on advancing cancer therapies through clinical and preclinical research.
Exelixis's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Exelixis offers CABOMETYX and COMETRIQ.
Yes, Exelixis is publicly traded on NASDAQ under the ticker symbol EXEL.
Exelixis has made 3 acquisitions, including Agritope, X-Ceptor Therapeutics, and Xceptor.
Exelixis has 3 investors. Key investors include HHS, European Union, and OSTI.GOV.
The ticker symbol of Exelixis is EXEL on NASDAQ.